| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	
 
																	
 
																	Rallybio Corporation (NASDAQ: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative...
 
																	
 
																	 
																	Rallybio (NASDAQ:RLYB) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.24) by 1...
 
																	
 
																	
